SCHEMBL1663181

SCHEMBL1663181

O=C(O)c1ccc(NCc2ccc(F)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 7/20 0.64
P4HTM Q9NXG6 1/20 0.63
MITF O75030 1/20 0.57
STING1 Q86WV6 1/20 0.57
BCL2L1 Q07817 1/20 0.53
BAD Q92934 1/20 0.53
NR4A2 P43354 1/20 0.53
HSD11B1 P28845 1/20 0.52
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.51
HSD17B10 Q99714 1/20 0.51
CTDSP1 Q9GZU7 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
MAPT P10636 1/20 0.51
ALOX15 P16050 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20183614 0.95 PPARA (0.72) PPARAP4HTMMITFSTING1BCL2L1
SCHEMBL4418236 0.91 CA1 (0.59) ALDH1A1POLBHPGDHSD17B10CTDSP1
SCHEMBL27833708 0.85 MITF (0.56) PPARAMITFBCL2L1BADNR4A2
SCHEMBL11257466 0.85 MITF (0.56) PPARAMITFBCL2L1BADNR4A2
SCHEMBL11246349 0.84 CA1 (0.69) ALDH1A1POLBHPGDHSD17B10CTDSP1
SCHEMBL1446643 0.84 CA1 (0.70) ALDH1A1POLBHPGDHSD17B10CTDSP1
SCHEMBL5211384 0.84 ALDH1A1 (0.65) ALDH1A1POLBHPGDHSD17B10CTDSP1
SCHEMBL30690063 0.83 HDAC1 (0.72) PPARAP4HTMALDH1A1GAAHDAC1
SCHEMBL10055033 0.83 LMNA (0.61) P4HTMALDH1A1POLBHPGDHSD17B10
SCHEMBL6419238 0.83 LMNA (0.61) P4HTMALDH1A1POLBHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4178385-A Method for treating hyperlipidemia in primates using 4-((4-fluorophenylmethyl)amino)benzoic acid THE DOW CHEMICAL COMPANY (US) 1979-12-11 US claimed
EP-2344456-B1 NOVEL POTASSIUM CHANNEL BLOCKER JAPAN TOBACCO INC (JP) 2018-07-25 EP disclosed
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
CN-102656141-B Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof LIGAND PHARMACEUTICALS INC. (US) 2016-04-06 CN disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
EP-2642994-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS Ligand Pharmaceuticals Incorporated (US) 2013-10-02 EP disclosed
CN-103282034-A Use of hematopoietic growth factor mimetics LIGAND PHARM INC 2013-09-04 CN disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed
US-20100087437-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed
WO-2010023445-A1 NOVEL POTASSIUM CHANNEL BLOCKER XENTION LIMITED (GB) 2010-03-04 WO disclosed
US-4362892-A ARALKYLANILINES, ANTICHOLESTEROL AGENTS BEECHAM GROUP LIMITED (GB) 1982-12-07 US disclosed
US-4207330-A Method for treating hyperglycemia in mammals using arylamino benzoic acids THE DOW CHEMICAL COMPANY (US) 1980-06-10 US disclosed
US-4206145-A ALKANOYL-SUBSTITUTED ARALKYLAMINES BEECHAM GROUP LIMITED (GB) 1980-06-03 US disclosed
US-4178385-A Method for treating hyperlipidemia in primates using 4-((4-fluorophenylmethyl)amino)benzoic acid THE DOW CHEMICAL COMPANY (US) 1979-12-11 US disclosed
US-4178385-A Method for treating hyperlipidemia in primates using 4-((4-fluorophenylmethyl)amino)benzoic acid THE DOW CHEMICAL COMPANY (US) 1979-12-11 US disclosed
US-4178385-A Method for treating hyperlipidemia in primates using 4-((4-fluorophenylmethyl)amino)benzoic acid THE DOW CHEMICAL COMPANY (US) 1979-12-11 US disclosed
US-4143151-A METHOD FOR TREATING HYPERGLYCEMIA IN MAMMALS USING ARYLAMINO BENZOIC ACIDS THE DOW CHEMICAL COMPANY (US) 1979-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL PPARA 1749/4885P4HTM 324/4885MITF 364/4885
US-20100087437-A1 Novel Potassium Channel Blockers KCNB1, KCNJ2, KCNJ11 PPARA 4487/4885P4HTM 1903/4885MITF 3862/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF PPARA 1587/4885P4HTM 770/4885MITF 452/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF PPARA 1587/4885P4HTM 770/4885MITF 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.